131 related articles for article (PubMed ID: 21953896)
1. The discovery of compounds that stimulate the activity of kallikrein-related peptidase 3 (KLK3).
Härkönen HH; Mattsson JM; Määttä JA; Stenman UH; Koistinen H; Matero S; Windshügel B; Poso A; Lahtela-Kakkonen M
ChemMedChem; 2011 Dec; 6(12):2170-8. PubMed ID: 21953896
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase 3 (KLK3).
Ylikangas H; Mattsson JM; Stenman UH; Koistinen H; Poso A; Lahtela-Kakkonen M
ChemMedChem; 2016 Sep; 11(18):2043-9. PubMed ID: 27465435
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity and inhibition of human kallikrein-related peptidase 3 (KLK3 or PSA) activated with sodium citrate and glycosaminoglycans.
Andrade D; Assis DM; Lima AR; Oliveira JR; Araujo MS; Blaber SI; Blaber M; Juliano MA; Juliano L
Arch Biochem Biophys; 2010 Jun; 498(1):74-82. PubMed ID: 20371359
[TBL] [Abstract][Full Text] [Related]
4. Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2.
Pakkala M; Weisell J; Hekim C; Vepsäläinen J; Wallen EA; Stenman UH; Koistinen H; Närvänen A
Amino Acids; 2010 Jun; 39(1):233-42. PubMed ID: 19967419
[TBL] [Abstract][Full Text] [Related]
5. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
6. KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?
Koistinen H; Künnapuu J; Jeltsch M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948344
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells.
Mattsson JM; Laakkonen P; Kilpinen S; Stenman UH; Koistinen H
Biol Chem; 2008 Jun; 389(6):765-71. PubMed ID: 18627292
[TBL] [Abstract][Full Text] [Related]
8. Very low PSA concentrations and deletions of the KLK3 gene.
Rodriguez S; Al-Ghamdi OA; Burrows K; Guthrie PA; Lane JA; Davis M; Marsden G; Alharbi KK; Cox A; Hamdy FC; Neal DE; Donovan JL; Day IN
Clin Chem; 2013 Jan; 59(1):234-44. PubMed ID: 23169475
[TBL] [Abstract][Full Text] [Related]
9. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
10. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.
Lawrence MG; Lai J; Clements JA
Endocr Rev; 2010 Aug; 31(4):407-46. PubMed ID: 20103546
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of peptides as protease inhibitors and stimulators.
Koistinen H; Hekim C; Wu P; Närvänen A; Stenman UH
Methods Mol Biol; 2014; 1088():147-58. PubMed ID: 24146402
[TBL] [Abstract][Full Text] [Related]
12. Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism.
Soualmia F; Bosc E; Amiri SA; Stratmann D; Magdolen V; Darmoul D; Reboud-Ravaux M; El Amri C
Biol Chem; 2018 Sep; 399(9):1073-1078. PubMed ID: 29641412
[TBL] [Abstract][Full Text] [Related]
13. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract][Full Text] [Related]
14. Major role of human KLK14 in seminal clot liquefaction.
Emami N; Deperthes D; Malm J; Diamandis EP
J Biol Chem; 2008 Jul; 283(28):19561-9. PubMed ID: 18482984
[TBL] [Abstract][Full Text] [Related]
15. Development of molecules stimulating the activity of KLK3 - an update.
Koistinen H; Wallén E; Ylikangas H; Meinander K; Lahtela-Kakkonen M; Närvänen A; Stenman UH
Biol Chem; 2016 Dec; 397(12):1229-1235. PubMed ID: 27383882
[TBL] [Abstract][Full Text] [Related]
16. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D.
Jha SK; Rauniyar K; Chronowska E; Mattonet K; Maina EW; Koistinen H; Stenman UH; Alitalo K; Jeltsch M
Elife; 2019 May; 8():. PubMed ID: 31099754
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J;
Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918
[TBL] [Abstract][Full Text] [Related]
18. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
19. Long terminal repeats act as androgen-responsive enhancers for the PSA-kallikrein locus.
Lawrence MG; Stephens CR; Need EF; Lai J; Buchanan G; Clements JA
Endocrinology; 2012 Jul; 153(7):3199-210. PubMed ID: 22597536
[TBL] [Abstract][Full Text] [Related]
20. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.
Skala W; Utzschneider DT; Magdolen V; Debela M; Guo S; Craik CS; Brandstetter H; Goettig P
J Biol Chem; 2014 Dec; 289(49):34267-83. PubMed ID: 25326387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
